Department of Thoracic Surgery and State Key Laboratory of Genetic Engineering, Fudan University Shanghai Cancer Center, Shanghai, China; Institute of Thoracic Oncology, Fudan University, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Department of Radiology, Fudan University Shanghai Cancer Center, Shanghai, China; Institute of Thoracic Oncology, Fudan University, Shanghai, China.
Chest. 2021 Mar;159(3):1265-1272. doi: 10.1016/j.chest.2020.10.076. Epub 2020 Nov 14.
Our previous study revealed that intraoperative frozen section (FS) analysis could differentiate invasive lung adenocarcinoma (LUAD) accurately from preinvasive lesions. However, few articles have analyzed the clinical impact of FS errors such as underestimation of invasive adenocarcinomas (IACs), and whether complementary therapy is needed remains controversial.
What is the prognosis of patients undergoing limited resection for invasive LUAD misdiagnosed as atypical adenomatous hyperplasia (AAH), adenocarcinoma in situ (AIS), or minimally invasive adenocarcinoma (MIA) by intraoperative FS analysis?
From 2012 through 2018, data on 3031 patients undergoing sublobar resection of AAH, AIS, or MIA diagnosed by FS analysis were collected. The concordance rate between FS analysis and final pathologic results was evaluated. To assess the clinical significance of a discrepancy between FS and final pathologic results, patients with final pathologic results of IAC were identified for prognostic evaluation.
When AAH, AIS, and MIA were classified together as a group, the overall concordance rate between FS and final pathologic results was 93.7%, and 192 patients (6.3%) received an upgraded diagnosis from the final pathologic results. Misdiagnosed IACs consisted of 94 patients (48.9%) with lepidic-predominant adenocarcinoma, 77 patients (40.1%) with acinar predominant adenocarcinoma, 19 patients (9.9%) with papillary predominant adenocarcinoma, one patient with solid predominant adenocarcinoma, and one patient with invasive mucinous adenocarcinoma. Among these patients, no positive N1 or N2 lymph node findings were observed. Moreover, the 5-year recurrence-free survival was still 100%, although the final pathologic results turned out to be IAC.
Patients undergoing limited resection of invasive LUAD misdiagnosed as AAH, AIS, or MIA by FS analysis showed excellent prognoses. Sublobar resection guided by FS diagnosis would be adequate for these underestimated cases of invasive LUAD.
我们之前的研究表明,术中冰冻切片(FS)分析可以准确地区分浸润性肺腺癌(LUAD)与早期病变。然而,很少有文章分析 FS 分析中低估浸润性腺癌(IAC)等错误的临床影响,是否需要补充治疗仍存在争议。
术中 FS 分析误诊为不典型腺瘤样增生(AAH)、原位腺癌(AIS)或微浸润性腺癌(MIA)的浸润性 LUAD 患者行局限性切除的预后如何?
2012 年至 2018 年,收集了 3031 例经 FS 分析诊断为 AAH、AIS 或 MIA 行亚肺叶切除术患者的数据。评估 FS 分析与最终病理结果的一致性。为评估 FS 与最终病理结果之间差异的临床意义,对最终病理结果为 IAC 的患者进行预后评估。
当 AAH、AIS 和 MIA 一起分类时,FS 与最终病理结果的总体一致性率为 93.7%,192 例(6.3%)患者的最终病理结果被升级诊断。误诊的 IAC 包括 94 例(48.9%)以贴壁生长为主的腺癌、77 例(40.1%)以腺泡生长为主的腺癌、19 例(9.9%)以乳头生长为主的腺癌、1 例以实体生长为主的腺癌和 1 例以浸润性黏液腺癌。这些患者中均未发现阳性 N1 或 N2 淋巴结。此外,尽管最终病理结果为 IAC,但这些患者的 5 年无复发生存率仍为 100%。
FS 分析误诊为 AAH、AIS 或 MIA 的浸润性 LUAD 患者的预后良好。对于这些低估的浸润性 LUAD 病例,FS 诊断指导的亚肺叶切除术是足够的。